{"id":"cebranopadol-100-g","safety":{"commonSideEffects":["nausea","dizziness","constipation","somnolence","vomiting"],"contraindications":["hypersensitivity to cebranopadol","severe respiratory depression","acute or severe bronchial asthma"]},"_chembl":{"chemblId":"CHEMBL2364605","moleculeType":"Small molecule","molecularWeight":"378.49"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"NOP receptor and opioid receptors (mu, delta, kappa)","explanation":"Cebranopadol is a highly potent analgesic that activates both the nociceptin receptor (NOP) and classical opioid receptors. This dual mechanism may offer effective pain control with a potentially improved side effect profile compared to traditional opioids, including reduced respiratory depression and abuse liability.","oneSentence":"Cebranopadol acts as a dual agonist at both nociceptin/orphanin FQ peptide (NOP) and opioid receptors to provide pain relief."},"_scrapedAt":"2026-03-28T01:50:14.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123795,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"oxycodone","brand":"OxyContin","company":"Purdue Pharma","rationale":"Traditional opioid analgesic for moderate to severe pain"},{"name":"tapentadol","brand":"Nucynta","company":"Collegium Pharmaceutical","rationale":"Dual mechanism opioid with norepinephrine reuptake inhibition"},{"name":"hydromorphone","brand":"Dilaudid","company":null,"rationale":"Potent opioid analgesic for severe pain management"}],"description":"Cebranopadol 100 µg is an investigational analgesic being developed by Tris Pharma, Inc. for pain management. It represents a novel approach to treating moderate to severe pain conditions and is currently in Phase 2 clinical development.","indications":{"approved":[{"status":"investigational","condition":"Chronic pain","patientPopulation":"Adult patients requiring opioid-level analgesia"},{"status":"investigational","condition":"Acute pain","patientPopulation":"Adult patients with moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT05256108","phase":"PHASE1","title":"Assessment of Abuse Potential of Cebranopadol in Humans","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2022-03-28","conditions":"Human Abuse Potential","enrollment":38},{"nctId":"NCT01939366","phase":"PHASE2","title":"Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-09-27","conditions":"Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus","enrollment":699}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cebranopadol 100 µg","genericName":"Cebranopadol 100 µg","companyName":"Tris Pharma, Inc.","companyId":"tris-pharma-inc","firstApprovalDate":"","aiSummary":"Cebranopadol 100 µg is a small molecule that acts as a nociceptin receptor agonist. It is being studied for its efficacy and safety in treating chronic pain, diabetic neuropathies, and diabetic patients with chronic pain caused by nerve damage.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}